WALDENSTROM MACROGLOBULINEMIA

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study tests whether combining three drugs—zanubrutinib, bendamustine, and rituximab—can achieve a very good partial response or better in people with untreated Waldenström macroglobulinemia, a rare blood cancer. About 55 participants will receive the combination therapy. The…

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of targeted drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test whether carefully managing any new or wors…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests a drug called venetoclax in about 14 adults in Japan who have a rare blood cancer (Waldenström macroglobulinemia) that has returned or not responded to prior therapy. Participants take venetoclax pills daily for up to 28 months. The goal is to see if the drug can…

This study tests whether a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) given for a limited time can effectively control Waldenström's macroglobulinemia, a rare blood cancer. About 40 adults who have not yet been treated for this condition will participat…

This study compares two treatment approaches for people with previously untreated Waldenstrom's macroglobulinemia, a rare blood cancer. One group gets a BTK inhibitor (ibrutinib plus rituximab or zanubrutinib alone), while the other gets venetoclax plus rituximab. The goal is to …

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia). The main goals are to check safety, find the best dose, and see how the body handles the drug. Participants must have a confirmed diagnosis and be …

This study tests whether a combination of two drugs, venetoclax and rituximab, works better than standard chemotherapy for people with untreated Waldenström's macroglobulinemia, a rare blood cancer. About 80 participants will receive either the drug combo or chemo, and researcher…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study is testing whether an antibody drug called epcoritamab can help control Waldenstrom Macroglobulinemia, a rare blood cancer, in patients who have already received previous treatments. The trial will enroll 20 participants to measure how well their cancer responds to thi…

This study aims to find genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or tissue samples from up to 10,000 participants to understand how these changes cause cancer to progress. The goal…

This study is observing people with Waldenström macroglobulinemia (a rare blood cancer) who are taking the drug zanubrutinib. Researchers want to see how well the drug works and how safe it is, especially in people with certain genetic mutations and from racial and ethnic minorit…

This study follows up to 1,000 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, or related conditions to learn how these diseases progress over time. Participants receive no treatment as part of the study; instead, t…

This study is creating a national registry of 1,000 people in Spain diagnosed with Waldenström macroglobulinemia or a related condition (IgM-MGUS) over the past 30 years. Researchers will review medical records to understand patient characteristics, treatments used, and long-term…

This study explores whether detecting tumor DNA in the blood after 6 months of treatment can help predict if Waldenström Macroglobulinemia will return within 3 years. Researchers will follow 90 patients who need treatment for this slow-growing blood cancer. The goal is to improve…